Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
Location status: Recruiting
Location contact
Louise Davies, MD, MS
PRINCIPAL_INVESTIGATOR
Michaela M Geffert, BS
CONTACT
NCT Number: NCT06220656
This is a pilot study to compare two ways of managing newly identified thyroid nodules that are likely to be cancerous based on ultrasound result and which under usual care would undergo immediate biopsy.
The main goals of this pilot study are 1) compare anxiety at 6 months in each treatment arm using the validated instrument Anxiety-CA, 2) measure thyroid quality of life in each treatment arm
Participants will be randomized to one of two groups:
1. immediate biopsy (usual care) 2. Active monitoring (serial ultrasound based monitoring and close clinical follow-up)
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Lebanon, New Hampshire, 03756, United States
Location status: Recruiting
Louise Davies, MD, MS
PRINCIPAL_INVESTIGATOR
Michaela M Geffert, BS
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients who fall into one of the following categories will NOT be eligible for this study:
TRAIL Pilot Integrated QRI: Inclusion/Exclusion Criteria
Inclusion criteria
for Study Patient Participants:
Exclusion criteria
for Study Patient Participants:
-Patients who are not willing to allow audio recorder presence and/or not willing to be interviewed by QRI team will be excluded from this study.
Inclusion criteria
for Study Staff Participants:
Exclusion criteria
for Study Staff Participants:
-Staff members who are not willing to participate in audio taping of recruitment discussions and/or interviews with QRI team about their views of the study will be excluded.
Local anesthetic is usually given and a small needle is used to take cells from the thyroid under ultrasound guidance through several 'passes' and placed into specialized media for pathology evaluation.
Ultrasound and a check-up at 6 months. Depending on ultrasound results, either biopsy and further care (as for the treatment arm called 'biopsy'), or continue with active monitoring.
Time frame: 6 months after randomization
Rate of anxiety will be measured using Anxiety-CA instrument PROMIS-Anxiety Short form. Each question has five response options ranging in value from one to five. (1 = never experiencing a type of distressing emotion; 5 = always feeling that emotion). To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For the adult PROMIS Anxiety 7a short form, a raw score of 10 converts to a T-score of 46.7 with a standard error (SE) of 2.6.
Time frame: 6 months after randomization.
Representativeness will be compared in terms of age in years (continuous), biological male or female (categorical), and race/ethnicity (categorical).
Time frame: 6 months after randomization
Rate of completion of patient reported outcomes and number of participants who withdraw from study or are lost to follow-up.
Time frame: 6 months after randomization.
A needle biopsy is a procedure to obtain samples of tissue or cells from thyroid nodule or lymph nodes to reveal whether a nodule is a benign tumor or cancer. Bethesda classification (ordinal) will be used. The Bethesda system identifies six diagnostic categories on thyroid nodule cytopathology. Each category is linked to a malignancy risk. Categories are as follows: Category I (Nondiagnostic), Category II (Benign), Category III (Atypical of undetermined significance), Category IV (Suspicious for follicular neoplasm), Category V (suspicious for malignancy), Category VI (Malignant). If Cytology results shows Bethesda V or VI, then histology (categorical) will be performed.
Time frame: 6 months after randomization.
Histologic examination (Categorical) will be performed to make diagnosis. Histology is a medical practice to review tissues under microscope to identify potential changes in a suspected tissue. The histological exam will help to diagnose if cancer is present or not and to find out the histologic type of the suspected tissue. The histologic types for thyroid cancer are as follows: Papillary, follicular, oncocytic, medullary, and anaplastic.
Time frame: Baseline and 6 months after randomization.
If patient is on active monitoring, then the nodule size will be followed with ultrasound exams.
Time frame: 3 and 6 months post randomization
The ThyPRO survey is a quality-of-life measure designed to evaluate how thyroid disease has affected the participant's life. Domains being used from this measure for the pilot study include symptoms (8 items), tiredness (2 items), and memory and concentration (3 items). Answer choices range from 1 (not at all) to 5 (very much) with higher scores indicating worse quality of life.
Contact information is provided by the study sponsor or research team.
Dartmouth-Hitchcock Medical Center
Other
ThyRoid Active Monitoring and Intervention Longitudinal (TRAIL) Study: Feasibility and Pilot
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03469310
Agnosia, Chemically-Induced Disorders
Edinburg, Texas, United States
View Trial DetailsNCT03031639
Endocrine Gland Neoplasms, Endocrine System Diseases
Muang, Khonkaen, Thailand
View Trial DetailsNCT02758158
Endocrine Gland Neoplasms, Endocrine System Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT01792492
Endocrine Gland Neoplasms, Endocrine System Diseases
Boston, Massachusetts, United States
View Trial Details